Tumor-imaging compounds show promise, Molecular Insight says

12/30/2008 | Mass High Tech (Boston)

Molecular Insight Pharmaceuticals said preliminary trial results showed that its molecular-imaging compounds, MIP-1072 and MIP-1095, exhibited high affinity to a protein expressed by prostate tumors. The company said it intends to finish early-stage trials of the compounds by the first half of next year.

View Full Article in:

Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN